{"id":"NCT02157948","sponsor":"Amgen","briefTitle":"A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis","officialTitle":"A Multicenter, Double-blind, Randomized Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05","primaryCompletion":"2015-07","completion":"2015-07","firstPosted":"2014-06-06","resultsPosted":"2017-08-16","lastUpdate":"2017-08-16"},"enrollment":394,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Postmenopausal Osteoporosis"],"interventions":[{"type":"DRUG","name":"Denosumab (CP2)","otherNames":["XGEVAÂ®"]},{"type":"DRUG","name":"Denosumab (CP4)","otherNames":[]}],"arms":[{"label":"Denosumab CP2","type":"ACTIVE_COMPARATOR"},{"label":"Denosumab CP4","type":"EXPERIMENTAL"}],"summary":"This study will compare the effect of denosumab produced by two different manufacturing processes on bone mineral density at the lumbar spine in postmenopausal women with osteoporosis.","primaryOutcome":{"measure":"Percent Change From Baseline in Lumbar Spine BMD","timeFrame":"Baseline and Month 12","effectByArm":[{"arm":"Denosumab CP2","deltaMin":5.78,"sd":3.44},{"arm":"Denosumab CP4","deltaMin":5.73,"sd":3.08}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"},{"comp":"OG000 vs OG001","p":"< 0.001"}]},"eligibility":{"minAge":"55 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":23,"countries":["United States","Canada","Denmark","Poland"]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":196},"commonTop":["Nasopharyngitis","Arthralgia"]}}